Janssen Seeks FDA Approval of New Darzalex Subcutaneous Formulation

Date : 07/12/2019 @ 5:38PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 131.33  0.0 (0.00%) @ 12:16AM

Janssen Seeks FDA Approval of New Darzalex Subcutaneous Formulation

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Johnson and Johnson Charts.
   By Stephen Nakrosis 

The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said Friday it submitted an application with the U.S. Food and Drug Administration seeking approval of its new subcutaneous formulation of Darzalex, or daratumumab, for certain patients with multiple myeloma.

Janssen said the Biologics License Application was supported by data from its Phase 3 Columba study, which included 522 patients, and data from the Phase 2 Pleiades study, which included 240 patients.

"The Darzalex subcutaneous formulation showed non-inferiority to the existing IV formulation, both as a monotherapy and in combination with common background therapies, while administered with a considerably shorter infusion time. We look forward to working closely with the FDA in their review of the data supporting this regulatory application," said Craig Tendler, vice president, clinical development and global medical affairs, oncology, Janssen Research & Development.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

July 12, 2019 12:23 ET (16:23 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.